{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T11:40:42.824645",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 57,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "survival",
        "event-free survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (general)",
        "progression-free survival",
        "progression-free survival (RECIST 1.1 criteria)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1; blinded independent central review)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "objective response rate (RECIST 1.1 criteria)",
        "overall response rate",
        "response rate",
        "response rates",
        "disease control rate",
        "complete response (RECIST 1.1)",
        "partial response (RECIST 1.1)",
        "time to response"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "duration of response",
        "treatment duration",
        "duration of treatment",
        "dropout rate",
        "treatment discontinuation due to adverse events",
        "dose modifications"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (AEs)",
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "grade 3 or higher adverse events",
        "grade 3-4 adverse event rate",
        "adverse event rate",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious side effects on the skin",
        "severe adverse events",
        "severe adverse events (liver disorders)",
        "interstitial lung disease (severe AE)",
        "liver disorders (severe AEs)",
        "stomatitis (AE)",
        "peripheral oedema (AE)",
        "peripheral neuropathy (AE)",
        "alopecia (AE)",
        "blood and lymphatic system disorders (AE)",
        "fatigue (AE)",
        "fatigue",
        "fever (AE)",
        "fever",
        "infections and infestations (AE)",
        "diarrhoea",
        "nausea",
        "neutropenia",
        "anaemia",
        "headache",
        "chest pain",
        "dyspnoea",
        "cough",
        "ALT increase",
        "AST increase",
        "febrile neutropenia",
        "mortality-related toxicity"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious side effects on the skin",
        "mortality-related toxicity"
      ],
      "discontinuations": [
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF (Brief Pain Inventory - Short Form)",
        "FACT-G GP5 (Functional Assessment of Cancer Therapy - General, item GP5)",
        "PGI-C (Patient Global Impression of Change)",
        "PGIC (Patient Global Impression of Change)",
        "PGIS (Patient Global Impression of Severity)",
        "EQ-5D visual analogue scale (EQ-5D VAS)",
        "EQ-5D-5L",
        "visual analogue scale (progression-free health state)",
        "visual analogue scale (EQ-5D-5L)",
        "NSCLC-SAQ (NSCLC Symptom Assessment Questionnaire)",
        "PRO-CTCAE (patient-reported outcome version of the Common Terminology Criteria for Adverse Events)",
        "item GP5 of the FACT-G"
      ],
      "functional_status": [
        "physical functioning deterioration",
        "physical benefits",
        "functional status"
      ],
      "symptom_measures": [
        "symptomatology (patient-reported)",
        "symptom control",
        "changes in cancer-specific symptoms",
        "changes in overall health status",
        "overall health status deterioration",
        "health status (patient-reported)",
        "health-related quality of life",
        "health-related quality of life (measured by time to death)",
        "quality of life",
        "psychological benefits"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility values (time-to-death approach)",
        "utility values (health-state approach)",
        "disutility associated with intravenous administration"
      ],
      "resource_utilization": [
        "resource utilization"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "treatment duration",
        "dose modifications"
      ],
      "biomarkers": [
        "biomarkers"
      ]
    }
  }
}